晚期支气管肺腺癌一线靶向治疗的疗效对比分析  

Analysis of effectiveness of targeted agents as first line treatment for advanced adenocarcinoma of the lung

作　　者：张淑立[1] 王毅[1] 刘学东[1] 葛云洁[1] 

机构地区：[1]青岛市市立医院呼吸科,山东青岛266011

出　　处：《中国医药科学》2015年第2期177-179,共3页China Medicine And Pharmacy

摘　　要：目的观察晚期支气管肺腺癌一线靶向治疗EGFR检测与否的近期临床疗效对比分析。方法回顾性分析2010年1月-2014年1月收治的晚期支气管肺腺癌患者42例,所有患者均为靶向治疗的优势人群,其中A组患者20例,均为表皮生长因子受体（EGFR）突变患者,B组患者22例,未行EGFR基因检测。所有患者分别服用吉非替尼、埃克替尼,观察两组患者的临床疗效。结果 A组患者中,完全缓解0例,部分缓解15例（75.0%）,疾病稳定3例（15.0%）,疾病进展2例（10.0%）,客观有效率为75.0%,疾病控制率为90.0%。B组患者中,完全缓解0例,部分缓解15例（68.2%）,疾病稳定4例（18.2%）,疾病进展3例（13.6%）,客观有效率为68.2%,疾病控制率为86.4%。两组患者的客观有效率、疾病控制率差异无统计学意义（P〉0.05）。结论患支气管肺腺癌的优势人群一线靶向治疗近期疗效肯定,对于无条件进行EGFR基因检测的优势人群,一线靶向治疗同样有较高的近期临床疗效。Objective To evaluate EGFR detection on the effectiveness of targeted agents as first line treatment for advanced adenocarcinoma of the lung. Methods 42 patients with advanced adenocarcinoma of the lung who had been treated with targeted agents as first line medicine from Jan. 2010 to Jan.2014 were retrospectively analyzed. 20 patients with EGFR mutations were assigned to group A, and 22 patients without detection of EGFR were assigned to group B. All have been treated with gefitinib or icotinib. Results Among patients from group A, 15 patients got PR（75.0%）, 3 got SD（15.0%）, 2 got PD（10.0%）, and 0 got CR（0）. The objective response rate（OPR） was 75.0%, and the disease control rate（DCR） was 90.0%. Among patients from group B, 15 patients got PR（68.2%）, 4 got SD（18.2%）, 3 got PD（13.6%）, and 0 got CR（0）. The OPR was 68.2%, and the DCR was 86.4%. There were no differences of OPR and DCR between two groups（P〉0.05）. Conclusion The effectiveness of targeted agents as first line treatment for advanced adenocarcinoma of the lung was good, whether the detection of EGFR was available or not.

关 键 词：晚期肺腺癌 EGFR基因检测 治疗效果 

分 类 号：R734.2[医药卫生—肿瘤]